SynAct Pharma AB (STO:SYNACT)
Sweden · Delayed Price · Currency is SEK | Market Cap | 784.02M -28.6% |
| Revenue (ttm) | n/a |
| Net Income | -110.83M |
| EPS | -2.17 |
| Shares Out | 56.00M |
| PE Ratio | n/a |
| Forward PE | 13.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 424,807 |
| Average Volume | 313,347 |
| Open | 14.60 |
| Previous Close | 14.54 |
| Day's Range | 14.00 - 14.78 |
| 52-Week Range | 13.40 - 25.30 |
| Beta | 0.88 |
| RSI | 35.29 |
| Earnings Date | May 27, 2026 |
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ fa... [Read more]
Financial Performance
Financial StatementsNews
SynAct Pharma AB Transcript: CMD 2026
Key clinical data from three programs are expected in the next two quarters, driving a shift to active business development. The lead RA program targets early, high-activity patients with a novel, non-immunosuppressive therapy, while host-directed therapies for respiratory infections address major unmet needs. Strong financials and a dual-track strategy support broad partnering opportunities.
SynAct Pharma AB Quarterly report: Q4 2025
SynAct Pharma AB has published its Q4 2025 quarterly earnings report on February 18, 2026.
SynAct Pharma AB Annual report: Q4 2025
SynAct Pharma AB has published its Q4 2025 annual report on February 18, 2026.
SynAct Pharma AB Transcript: Life Science Summit 2025
Resomelagon is advancing in phase IIB trials for rheumatoid arthritis and host-directed viral infection therapies, with major data readouts and a dengue study expected next year. The approach targets immune modulation, aiming to improve outcomes and reduce side effects.
SynAct Pharma AB Quarterly report: Q3 2025
SynAct Pharma AB has published its Q3 2025 quarterly earnings report on October 30, 2025.
SynAct Pharma AB Quarterly report: Q2 2025
SynAct Pharma AB has published its Q2 2025 quarterly earnings report on August 20, 2025.
SynAct Pharma AB Transcript: CMD 2025
Lead RA study is on track for year-end data, with new PMR and dengue programs broadening the pipeline. Recent capital raises and a credit facility secure funding through 2026, supporting clinical and business development efforts targeting licensing or acquisition deals.
SynAct Pharma AB Slides: Company Presentation
SynAct Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2025.
SynAct Pharma AB Quarterly report: Q1 2025
SynAct Pharma AB has published its Q1 2025 quarterly earnings report on May 27, 2025.
SynAct Pharma AB Annual report: Q4 2024
SynAct Pharma AB has published its Q4 2024 annual report on February 18, 2025.
SynAct Pharma AB Quarterly report: Q4 2024
SynAct Pharma AB has published its Q4 2024 quarterly earnings report on February 18, 2025.
SynAct Pharma AB Quarterly report: Q3 2024
SynAct Pharma AB has published its Q3 2024 quarterly earnings report on October 30, 2024.
SynAct Pharma AB Transcript: CMD 2024
A refocused strategy prioritizes the ADVANCE phase II study in newly diagnosed, high-activity RA patients, aiming for data by end of next year and subsequent partnering. Resomelagon offers a novel, immune-preserving approach with strong efficacy in the right subgroup, addressing a large unmet need in RA and attracting significant industry interest.
SynAct Pharma AB Press release: FY 2024
SynAct Pharma AB issued a press release on September 23, 2024, disclosing material business information to investors.
SynAct Pharma AB Slides: FY 2024
SynAct Pharma AB has posted slides in relation to its FY 2024 quarterly earnings report, which was published on September 23, 2024.
SynAct Pharma AB Quarterly report: Q2 2024
SynAct Pharma AB has published its Q2 2024 quarterly earnings report on August 20, 2024.
SynAct Pharma AB Quarterly report: Q1 2024
SynAct Pharma AB has published its Q1 2024 quarterly earnings report on May 31, 2024.
SynAct Pharma AB Slides: Status Update
SynAct Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on May 23, 2024.
SynAct Pharma AB Earnings Call Transcript: Q4 2023
SynAct Pharma AB Annual report: Q4 2023
SynAct Pharma AB has published its Q4 2023 annual report on February 23, 2024.
SynAct Pharma AB Earnings release: Q4 2023
SynAct Pharma AB released its Q4 2023 earnings on February 23, 2024, summarizing the period's financial results.
SynAct Pharma AB Earnings Call Transcript: Q3 2023
SynAct Pharma AB Quarterly report: Q3 2023
SynAct Pharma AB has published its Q3 2023 quarterly earnings report on October 24, 2023.
SynAct Pharma AB Transcript: Study Update
SynAct Pharma AB Press release: Study Update
SynAct Pharma AB issued a press release on September 13, 2023, disclosing material business information to investors.